GSK (LSE:GSK) Poised for Growth with Strong Sales, Strategic …
WEB4 days ago · GSK(LSE:GSK) is navigating a dynamic environment marked by both opportunities and challenges. Recent highlights include a robust 13% sales growth and strategic innovations in R&D, contrasted with ...
Press releases - GSK
WEBBrowse GSK global press releases issued since 2009. Search them by keyword or browse by year/business category. Press releases issued by our local operating companies can be viewed on our market websites.
GSK Announces Positive Topline Data on Co-Administration of …
WEB4 days ago · PHILADELPHIA, September 18, 2024 -- (BUSINESS WIRE)--GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine, Adjuvanted) when co-administered with SHINGRIX (Zoster Vaccine Recombinant ...
GSK Bets on Blood-Cancer Drug Comeback Amid Oncology Push
WEBSep 13, 2024 · Global News Select GSK Bets on Blood-Cancer Drug Comeback Amid Oncology Push Provided by Dow Jones. Sep 13, 2024 4:40pm ... GSK's revenue last year stood at 30.33 billion pounds ($39.80 billion ...
British drugmaker GSK moves mRNA flu vaccine to late-stage trials
WEBSep 12, 2024 · The data showed that a vaccine candidate produced positive immune responses against both A and B flu strains in younger and older adults, compared with the current standard treatments, GSK said. In July, GSK bought partner CureVac out of their alliance on influenza and COVID-19 vaccine development, boosting its messenger RNA credentials. GSK, one of the world's largest vaccine manufacturers ...
GSK makes a strong start to 2024 with improving outlook for the …
WEBMay 1, 2024 · Now expect 2024 turnover growth towards the upper part of 5% to 7% range; Core operating profit growth of 9% to 11% (previously 7% to 10%); Core EPS growth of 8% to 10% (previously 6% to 9%) Dividend declared of 15p for …
GSK announces positive results from DREAMM-8 phase III trial for ...
WEBMar 7, 2024 · GSK plc (LSE/NYSE: GSK) today announced positive headline results from an interim analysis of the DREAMM-8 phase III head-to-head trial evaluating Blenrep (belantamab mafodotin), in combination with pomalidomide plus dexamethasone (PomDex), versus a standard of care, bortezomib plus PomDex, as a second line and later treatment for relapsed or ...
GSK News
WEBStay updated on the latest news from GSK, a global healthcare company with innovative medicines, vaccines and consumer products.
US FDA approves GSK’s AREXVY, the world’s first respiratory …
WEBMay 3, 2023 · GSK plc (LSE/NYSE: GSK) today announced that the US Food and Drug Administration (FDA) has approved AREXVY (respiratory syncytial virus vaccine, adjuvanted) for the prevention of lower respiratory tract disease (LRTD) caused by respiratory syncytial virus (RSV) in individuals 60 years of age and older. This is the first RSV vaccine for older ...
GSK antibody drug reduces COPD attacks in trial
WEBSep 6, 2024 · Dive Brief: GSK on Friday said its Nucala medicine succeeded in a Phase 3 study of patients with chronic obstructive pulmonary disease, offering the British drugmaker another shot at an expanded approval for the drug. The trial, known as MATINEE, included COPD patients suffering from chronic bronchitis …